| Autor: |
Matsuo, F., Bergen, D., Faught, E., Messenheimer, J. A., Dren, A. T., Rudd, G. D., Lineberry, C. G. |
| Zdroj: |
Neurology (Ovid); November 1993, Vol. 43 Issue: 11 p2284-2291, 8p |
| Abstrakt: |
We evaluated the efficacy and safety of lamotrigine (300 and 500 mg/day) as add-on therapy in a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of 216 patients with refractory partial seizures. During 6 months of treatment, median seizure frequency decreased by 8 with placebo, 20 with 300 mg lamotrigine, and 36 with 500 mg lamotrigine. Seizure frequency decreased by ≥50 in one-third of the 500-mg group and one-fifth of the 300-mg group. Reductions in seizure frequency and seizure days were statistically significant, compared with placebo, for the 500-mg group but not the 300-mg group. Most adverse events were minor and resolved over time. Nine percent of patients on lamotrigine withdrew because of adverse experiences. Lamotrigine plasma concentrations appeared to be a linear function of dose, and the drug did not affect plasma concentrations of concomitant antiepileptic drugs. Lamotrigine was safe, effective, and well tolerated as add-on therapy for refractory partial seizures. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
